Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported that its Phase 3 trial evaluating fianlimab, a LAG-3 inhibitor, in combination with cemiplimab ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE